跳至主要内容
临床试验/NCT06031662
NCT06031662招募中不适用

Image-guided, Accelerated, Theta-burst Stimulation for the Treatment of Post-concussion Syndrome

Sunnybrook Health Sciences Centre2 个研究点 分布在 1 个国家目标入组 26 人开始时间: 2023年10月31日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
26
试验地点
2
主要终点
Rivermead Post Concussion Symptoms Questionnaire

研究概览

简要总结

TMS has been safely and reliably delivered at the Harquail Centre for over 5 years, with a primary focus on conventional rTMS protocols for treatment-resistant depression. Recently, the investgator team has gained the capability to deliver sham-controlled intermittent theta-burst stimulation (iTBS) rTMS. Unlike conventional high frequency rTMS, which was used in the previous sham-controlled rTMS PCS pilot study, iTBS is a patterned form of stimulation that recapitulates endogenous activity patterns of neural circuits pairing gamma frequency (50Hz) burst pulses coupled in a theta frequency rhythm (5Hz).12 iTBS delivers 600 pulses in just over 3 minutes with similar or greater effects on neural plasticity compared to conventional rTMS (taking over 30-45 minutes) and similar tolerability and efficacy in trials of depression. Furthermore, novel accelerated iTBS protocols stimulating the left dorsolateral prefrontal cortex (dlPFC) over 8-10 treatments, 50 minutes apart over a 5 day interval has recently demonstrated robust efficacy in depression and received recent FDA approval. Thus, accelerated iTBS can be delivered in a single week of treatment compared to 6 weeks with conventional rTMS methods. Finally, the investigators recently acquired the technology to integrate MRI neuroimage-guided stimulation, which would allow to target specific brain regions/networks implicated in PCS at high spatial resolution. No studies to date have investigated image-guided accelerated iTBS rTMS for the treatment of PCS.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Documented evidence of head trauma sufficiently severe to result in loss of consciousness, post-traumatic amnesia and/or acute altered mental status.
  • At least three symptoms including headache, dizziness, fatigue, irritability, insomnia, memory difficulties, concentration difficulties, mood dysregulation.
  • Onset of symptoms within 4 weeks following the head trauma.
  • Age 18-60, inclusive.
  • Persistence of PCS symptoms for at least 3 months but less than 12 months
  • Able to provide informed consent and comply with the study protocol
  • Patients will not be excluded solely on the basis of communication (i.e., non-English speaking) unless they have exclusion criteria that is the cause of the communication difficulties.

排除标准

  • Evidence of major structural neuroimaging abnormalities (e.g., intracranial hemorrhage, skull fracture or a large intracranial lesion)
  • History of prior rTMS therapy,
  • Contraindications to MRI (e.g., pacemaker, metallic implants etc.).
  • Ferromagnetic, non-removable metallic implants from above the clavicle with the exception of dental work.
  • Active personal injury litigation
  • History of seizure disorder, not including febrile seizures in childhood
  • Substance dependence within the last 6 months
  • Currently taking more than lorazepam 2 mg daily (or benzodiazepine equivalent) or any dose of an anticonvulsant (due to the potential to reduce rTMS efficacy)
  • Currently taking an antiepileptic medication
  • Mild and major comorbid medical conditions (as determined by investigators - e.g., neurological diseases, uncontrolled hypertension or diabetes, malignancy)
  • A major comorbid psychiatric disorder (as determined by investigators - e.g., schizophrenia or bipolar disorder) and/or psychosis at the time of study enrollment

结局指标

主要结局

Rivermead Post Concussion Symptoms Questionnaire

时间窗: 1 month post-treatment

RPQ, a validated measure of subjective global PCS symptoms.

次要结局

  • Montgomery-Åsberg Depression Rating Scale(Baseline, post treatment day 5, and post treatment 1 month)
  • Repeatable Battery for the Assessment of Neuropsychological Status(Baseline and post treatment 1 month)
  • The Behavior Rating Inventory of Executive Function(Baseline, post treatment day 5, and post treatment 1 month)
  • Headache Impact Test(Baseline and post treatment 1 month)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Dr. Sean Michael Nestor

clinician-investigator and interventional psychiatrist

Sunnybrook Health Sciences Centre

研究点 (2)

Loading locations...

相似试验